Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hepatic intra-arterial idarubicin TACE dosing study in intermediate-stage hepatocellular carcinoma
2021-001257-31Phase 4Completed
- Sponsor
- Uppsala University
- Start
- Jul 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of idarubicin in hepatocellular carcinoma (HCC) (2 arms), sponsored by Uppsala University. Primary endpoints: Plasma pharmacokinetics of idarubicin and idarubicinol and Safety and tolerability of idarubicin 10 mg vs 15 mg. Started Jul 2021; status: completed.
02
Drugs
idarubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2021-001257-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001257-31.